In direct compression tableting, the received Xixin Powder Veterinary Grade API is first classified by laser diffraction (ISO 13320-1:2020) to confirm that 90% of the volume distribution falls below 75 µm and that the median particle diameter is between 15 µm and 35 µm. The material is a powdered botanical API derived from Asari Radix et Rhizoma, and release is not limited to a single chemical marker; therefore, a chromatographic profile combined with residual moisture and particle size is used as the primary material control. Residual moisture is controlled below 6.0% by Karl Fischer titration per USP <921> because herbal powders above this threshold stick to punches and reduce hardness reproducibility on high-speed rotary presses. A direct compression batch is formulated at 20% w/w API, 72% microcrystalline cellulose PH102, 5% sodium starch glycolate, 2% crospovidone, 0.5% colloidal silicon dioxide, and 0.5% magnesium stearate. All powders are pre-screened through a 500 µm mesh, blended in a V-blender at 25 rpm for 15 minutes, with magnesium stearate added for the final 3 minutes to avoid overlubrication. Tap density of the unblended botanical fraction is commonly observed between 0.35 g/mL and 0.55 g/mL, so die fill depth is adjusted after bulk density testing per USP <616> to maintain a target tablet weight of 100 mg ± 5%. Compression force on a 10-station rotary press is set between 10 kN and 15 kN, with precompression at 2–4 kN to expel air from the low-density plant fraction; tablet hardness is held at 8–12 kp, and friability is measured per USP <1216> and must remain below 1.0%. Uniformity of dosage units is evaluated per USP <905> with an acceptance value not exceeding 15.0. If the tablet formulation requires more than 30% w/w API, direct compression is replaced by roller compaction because the fibrous lignocellulosic fraction reduces tensile strength and produces capping at higher compression forces. The terminal product is a 100 mg scored veterinary tablet for oral administration to non-food-producing companion animals in jurisdictions where the botanical API is authorized.

What Limits Sterile Filtration of Xixin Powder Suspensions?

Above 1 µm, insoluble lignocellulosic fragments make a 0.22 µm membrane sterilising filter unsuitable for the final Xixin Powder suspension; therefore, sterile filtration can be applied only to the aqueous vehicle before aseptic incorporation of the milled API. The sterile vehicle consists of sodium chloride 0.9% w/v, polysorbate 80 0.1% w/v, sodium carboxymethylcellulose 0.5% w/v, and a 10 mM phosphate buffer at pH 5.5; this vehicle is autoclaved at 121 °C for 15 minutes. The API fraction is treated with gamma irradiation at an absorbed dose of 5–10 kGy for bioburden reduction, but post-treatment assay of aristolochic acid I and II must be performed because radiation-induced degradation in complex botanical matrices is not reliably predictable. The sterile slurry is prepared by wet milling in a colloid mill with rotor-stator clearance of 100 µm and passed through a 75 µm mesh; the final suspension is filled as 20 mL into siliconised Type I glass vials and stoppered under aseptic conditions. Release testing includes sterility per USP <71>, bacterial endotoxins per USP <85> with a limit calculated from the product dose volume and target species weight, and subvisible particulate matter per USP <788>. Heat-labile volatile constituents preclude moist-heat terminal sterilisation above 60 °C, so dry-heat or radiation treatment remains the practical microbial control point. Closure compatibility is evaluated under accelerated storage conditions appropriate for the region because methyl eugenol and related volatile phenylpropanoids can migrate into standard rubber stoppers and alter extractables. The terminal product is an injectable suspension for veterinary administration, but regulatory acceptability in food-producing species is limited where aristolochic acid residues cannot be controlled below the regional maximum residue limit; in such cases the product is restricted to companion animals or non-food-producing horses.

Because hard gelatin capsule shells cross-link when exposed to low-moisture botanical powders, the encapsulation room is maintained at 40% relative humidity and 20–25 °C, and the filled capsule moisture is controlled below 5.0% using Karl Fischer or loss on drying. A representative fill at 25% w/w API contains 73% lactose monohydrate, 1% talc, 0.5% sodium lauryl sulfate, and 0.5% colloidal silicon dioxide; sodium lauryl sulfate improves wetting of the hydrophobic cuticular fragments and reduces static build-up during capsule filling. The blend is pre-compacted by slugging at 5–10 kN, then milled through a 1.0 mm screen to produce free-flowing granules before automatic capsule filling. Powder fill weight for a size 3 hard gelatin capsule is set at 400 mg ± 5%, delivering 100 mg of the botanical API per capsule; fill weight is monitored every 15 minutes during compounding. The terminal capsule is tested for disintegration in purified water at 37 ± 2 °C using USP <701>, with a limit of not more than 30 minutes. If a registered dissolution specification exists, USP <711> may be applied using 900 mL of 0.1 M hydrochloric acid and basket rotation at 50 rpm; published data for this specific Xixin Powder capsule configuration is limited, so dissolution acceptance criteria must be derived from pilot stability batches rather than assumed from compendial monographs. The capsule fill is not suited to direct encapsulation of raw botanical powder without a granulation step because the high elastic recovery of fibrous particles can cause fill weight variability greater than 5% RSD and unacceptable content uniformity risk.

Premix Homogeneity and Ordered Mixing Limits

Ordered mixing is applied to Xixin Powder premixes because the API fraction is a fine, low-density botanical powder that segregates from coarse carriers in simple tumble mixing. The carrier is ground rice hulls with a particle size of 0.5–1.0 mm, pre-dried to a moisture content below 10% and tested for mycotoxins; the carrier is charged into a horizontal ribbon blender equipped with spray bars. Mineral oil at 0.5% w/w is sprayed onto the tumbling carrier to create a binding film, then the botanical API with a d50 of 25–40 µm is added and mixed at 20 rpm for 10–20 minutes. The target premix concentration is 0.5% w/w (5 g/kg), with a 10-sample assay for each batch; the relative standard deviation must not exceed 5.0% to comply with medicated feed manufacturing practice under FDA 21 CFR 225. If the measured RSD exceeds 5.0%, mixing time is extended in 5-minute increments rather than increasing RPM, because higher shear can fracture the rice hull carrier and generate new segregable fines. The terminal premix is a 25 kg multi-wall paper bag with an inner polyethylene liner, intended for dilution into complete feed at rates determined by regional registration. Because aristolochic acid residues may be present, use in food-producing species is not assumed; the premix is generally restricted to non-food-producing animals or to jurisdictions with an explicit aristolochic acid limit and corresponding withdrawal period. The premix specification includes absence of Salmonella per USP <62> and total aerobic microbial count below 10⁴ CFU/g per USP <61>.

Orally administered powders for drinking-water or feed top-dressing require rapid wetting and suspension without using hygroscopic carriers that would cake in the sachet during shelf storage. The API is micromilled to a d90 below 75 µm and blended at 20% w/w with 79% lactose monohydrate and 1% colloidal silicon dioxide in a low-shear ribbon blender for 15 minutes. The blend is filled into foil-lined sachets under controlled humidity below 40% RH; the sachet material is a foil laminate with water vapour transmission rate below 0.1 g/m²/day to prevent moisture ingress in humid climates. Residual moisture is maintained below 6.0% so that the powder does not form lumps when added to drinking water. The terminal product is a metered sachet containing 1 g of API per unit, diluted into 10–100 L of drinking water according to regional label conditions; it is a delivery device, not a dose unit. Microbial quality is tested per USP <61> and USP <62> with absence of E. coli and Salmonella in a 25 g sample; because the powder is non-sterile, a bioburden limit of 10⁴ CFU/g total aerobic microbial count and 10² CFU/g total combined yeasts and moulds is typically applied. The hydrophobic botanical particles can float on the water surface; therefore, the formulation contains 1% colloidal silicon dioxide and, in some regional formulations, 0.1% polysorbate 80 to improve dispersibility, but the surfactant must be justified against the maximum daily intake for the target species. GMP manufacture follows the applicable veterinary premix or oral powder provisions under 21 CFR Part 212 or regional equivalent, and the batch record must record sieve analysis after final blending.

Granule Growth Kinetics in Fluid-Bed Processing with PVP K30

The granulation endpoint for a Xixin Powder/PVP K30 charge is controlled by loss on drying rather than by fixed spray time, because the mass transfer rate varies with inlet air humidity and product bed depth. A typical charge contains 15% w/w API, 80% mannitol/maize starch mixture, 3% povidone K30, and 2% sodium starch glycolate; the dry powders are preheated in the fluid-bed bowl to a product temperature of 30–35 °C before spraying. The binder solution is purified water containing PVP K30 at 2% w/w of the dry charge, sprayed at 10–20 g/min/kg through a 1.2 mm nozzle with atomising air pressure of 1.5 bar. Inlet air temperature is held at 55–60 °C; exhaust temperature and product temperature are recorded every 5 minutes. Endpoint is determined by loss on drying per USP <731> at 2.0–4.0%, corresponding to a moisture content that prevents both over-wetting and electrostatic breakage of the granules during subsequent sachet filling. The granulate is milled through a 1.5 mm conical sieve, then blended with 0.5% magnesium stearate for 3 minutes; the final granule size fraction between 0.2 mm and 0.7 mm is collected. Terminal granules are filled into sachets or bottles at an API dose equivalent of 100 mg per unit; flow through a 10 mm orifice should exceed 10 g/s to maintain acceptable filling accuracy on high-speed lines. Content uniformity is evaluated per USP <905> with a 10-unit sample and an acceptance value not exceeding 15.0. If the granulation endpoint is missed by 1% moisture, the oversprayed batch can form bridges in the nozzle filter bags and produce over-sized granules above 1.5 mm; such material must be re-milled rather than re-blended because drug distribution between granule size fractions becomes uneven.

When Oral Solutions Require Preservative Partitioning Across Botanical Solids

Preservative partitioning in oral liquids cannot be predicted from nominal concentration when Xixin Powder is present, because the dispersed botanical solids provide a sorptive surface area that depletes free preservative from the suspending medium. The vehicle is prepared in a stainless steel tank with purified water, a 10 mM citrate buffer at pH 4.5, sodium benzoate 0.1% w/v, potassium sorbate 0.1% w/v, and xanthan gum 0.3% w/v as a suspending agent; the preservative combination is chosen because benzoate ionises at higher pH and sorbate degrades under strong light, so pH and container opacity are controlled. The API is incorporated at 20% w/v under high-shear dispersion at 3,000 rpm for 20 minutes, then passed through a 75 µm mesh; the final product is filled into 1 L amber polyethylene terephthalate bottles with tamper-evident closures. Preservative efficacy is not assumed from nominal concentration because botanical solid particles can adsorb preservative molecules; the finished product is challenged per USP <51> using Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Candida albicans, and Aspergillus brasiliensis. If free preservative concentration drops below the minimum inhibitory concentration during stability, the preservative system must be increased or the fill volume reduced. The terminal product is an oral liquid for veterinary administration; it is labelled as a suspension with shaking before use, not as an intravenous or injectable product. The solution is tested for pH per Ph. Eur. 2.2.3, viscosity per USP <912> or rotational viscometer, and deliverable volume per USP <698>; microbial limits are specified by USP <61> and USP <62>. Storage below 25 °C and protected from light is required because the volatile fraction of the botanical material undergoes oxidative degradation under ultraviolet exposure.